Current understanding and future implications of sepsis-induced thrombocytopenia.
sepsis
sepsis-induced thrombocytopenia
thrombocytopenia
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
20
07
2020
revised:
10
11
2020
accepted:
11
11
2020
pubmed:
17
11
2020
medline:
30
7
2021
entrez:
16
11
2020
Statut:
ppublish
Résumé
Sepsis is a global health burden that needs intensive medical care. Thrombocytopenia in sepsis is well known to increase morbidity as well as mortality. Several studies have been performed both in animal models and in humans to understand the mechanism by which sepsis causes thrombocytopenia. Recent studies have shown that inhibiting thrombocytopenia improves outcomes in sepsis patients. Understanding these mechanisms to identify targets in use of newer treatment modalities besides using resuscitation measures, antibiotics and removal of thrombocytopenia inducing agent could potentially help us improve outcomes in sepsis.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
301-305Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801-810.
Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707-710.
Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;1644-1655.
Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840-851. https://doi.org/10.1056/NEJMra1208623
Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity. 2014;40:463-475.
Vincent JL, Marshall JC, Ñamendys-Silva SA, et al. Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit. Lancet Respir Med. 2014;2(5):380-386.
Sharma B, Sharma M, Majumder M, Steier W, Sangal A, Kalawar M. Thrombocytopenia in septic shock patients - a prospective observational study of incidence, risk factors and correlation with clinical outcome. Anaesth Intensive Care. 2007;35(6):874-880.
Baughman RP, Lower EE, Flessa HC, Tollerud DJ. Thrombocytopenia in the intensive care unit. Chest. 1993;104(4):1243-1247.
Vanderschueren S, De Weerdt A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med. 2000;28(6):1871-1876.
Venkata C, Kashyap R, Christopher Farmer J, Afessa B. Thrombocytopenia in adult patients with sepsis: incidence, risk factors, and its association with clinical outcome. J Intensive Care. 2013;1(1):9.
Rice TW, Wheeler AP. Coagulopathy in critically ill patients - Part 1: platelet disorders. Chest. 2009;136:1622-1630.
Morrell CN, Aggrey AA, Chapman LM, Modjeski KL. Emerging roles for platelets as immune and inflammatory cells. Blood. 2014;123:2759-2767.
Cognasse F, Hamzeh H, Chavarin P, Acquart S, Genin C, Garraud O. Evidence of Toll-like receptor molecules on human platelets. Immunol Cell Biol. 2005;83(2):196-198.
Yaguchi A, Lobo FLM, Vincent JL, Pradier O. Platelet function in sepsis. J Thromb Haemost. 2004;2(12):2096-2102.
de Stoppelaar SF, van't Veer C, van der Poll T. The role of platelets in sepsis. Thromb Haemost. 2014;112(4):666-677.
Gårdlund B, Sjölin J, Nilsson A, Roll M, Wickerts CJ, Wretlind B. Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis. 1995;172(1):296-301.
Schwertz H, Köster S, Kahr WHA, et al. Anucleate platelets generate progeny. Blood. 2010;115(18):3801-3809.
Segre E, Pigozzi L, Lison D, et al. May thrombopoietin be a useful marker of sepsis severity assessment in patients with SIRS entering the emergency department? Clin Chem Lab Med. 2014;52(10):1479-1483.
Huizinga EG, Tsuji S, Romijn R, et al. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science. 2002;297(5584):1176-1179.
Yin H, Stojanovic-Terpo A, Xu W, et al. Role for platelet glycoprotein Ib-IX and effects of its inhibition in endotoxemia-induced thrombosis, thrombocytopenia, and mortality. Arterioscler Thromb Vasc Biol. 2013;33(11):2529-2537.
Pu Q, Wiel E, Corseaux D, et al. Beneficial effect of glycoprotein IIb/IIIa inhibitor (AZ-1) on endothelium in Escherichia coli endotoxin-induced shock. Crit Care Med. 2001;29(6):1181-1188.
Beutler BA. TLRs and innate immunity. Blood. 2009;113(7):1399-1407.
Shiraki R, Inoue N, Kawasaki S, et al. Expression of Toll-like receptors on human platelets. Thromb Res. 2004;113(6):379-385.
Andonegui G, Kerfoot SM, McNagny K, Ebbert KVJ, Patel KD, Kubes P. Platelets express functional Toll-like receptor-4. Blood. 2005;106(7):2417-2423.
Aslam R, Speck ER, Kim M, et al. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood. 2006;107(2):637-641.
Stark RJ, Aghakasiri N, Rumbaut RE. Platelet-derived toll-like receptor 4 (Tlr-4) is sufficient to promote microvascular thrombosis in endotoxemia. PLoS One. 2012;7(7):e41254.
Zhang G, Han J, Welch EJ, et al. Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J Immunol. 2009;182(12):7997-8004.
Tsuchiya R, Kyotani K, ScottM A, et al. Role of platelet activating factor in development of thrombocytopenia and neutropenia in dogs with endotoxemia. Am J Vet Res. 1999;60(2):216-221.
Salat A, Bodingbauer G, Boehm D, et al. Changes of platelet surface antigens in patients suffering from abdominal septic shock. Thromb Res. 1999;95(6):289-294.
Stéphan F, Cheffi MA, Kaplan C, et al. Autoantibodies against platelet glycoproteins in critically ill patients with thrombocytopenia. Am J Med. 2000;108(7):554-560.
François B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H. Thrombocytopenia in the sepsis syndrome: Role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med. 1997;103(2):114-120.
Sheu JR, Hung WC, Wu CH, et al. Reduction in lipopolysaccharide-induced thrombocytopenia by triflavin in a rat model of septicemia. Circulation. 1999;99(23):3056-3062.
Hunt BJ. Bleeding and coagulopathies in critical care. N Engl J Med. 2014;370(9):847-859.
Johansson D, Shannon O, Rasmussen M. Platelet and neutrophil responses to Gram positive pathogens in patients with bacteremic infection. PLoS One. 2011;6(11):e26928.
Kinasewitz GT, Yan SB, Basson B, et al. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care. 2004;8(2):R82-R90.
Lippi G, Plebani M. EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact. Clin Chem Lab Med. 2012;50:1281-1285.
Stephan F, Hollande J, Richard O, Clieffi AU, Maicr-Redclspcrgcr M, Flahault A. Thrombocytopenia in a surgical ICU. Chest. 1999;115(5):1363-1370.
Lei W, Liang J, Chen WG, Ma XZ, Xu M, Du LL. Effectiveness and safety of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia. Zhonghua Zhong Liu Za Zhi. 2006;28(7):542-544.
Wan B, Zhang H, Fu H, et al. Recombinant human interleukin-11 (IL-11) is a protective factor in severe sepsis with thrombocytopenia: a case-control study. Cytokine. 2015;76(2):138-143.
Wu Q, Ren J, Wu X, et al. Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia: a prospective study. J Crit Care. 2014;29(3):362-366.
Wu Q, Ren J, Wang G, et al. Evaluating the safety and efficacy of recombinant human thrombopoietin among severe sepsis patients with thrombocytopenia: study protocol for a randomized controlled trial. Trials. 2015;16:220.
Lei X, Reheman A, Hou Y, et al. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost. 2013;111(2):279-289.
Li BX, Dai X, Yang Z, et al. First ex vivo and in vivo assessment of anfibatide, a novel glycoprotein Ib-IV-V complex antagonist, in healthy human volunteers in phase I clinical trial. J Thromb Haemost. 2013;11:23.
Sharron M, Hoptay CE, Wiles AA, et al. Platelets induce apoptosis during sepsis in a contact-dependent manner that is inhibited by GPIIb/IIIa blockade. PLoS One. 2012;7(7):e41549.
Rice TW, Wheeler AP, Bernard GR, et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med. 2010;38(8):1685-1694.
Roger T, Froidevaux C, Le Roy D, et al. Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci U S A. 2009;106(7):2348-2352.
Ranjith-Kumar CT, Duffy KE, Jordan JL, et al. Single-stranded oligonucleotides can inhibit cytokine production induced by human toll-like receptor 3. Mol Cell Biol. 2008;28(14):4507-4519.
Lahiri A, Lahiri A, Das P, Vani J, Shaila MS, Chakravortty D. TLR 9 activation in dendritic cells enhances salmonella killing and antigen presentation via involvement of the reactive oxygen species. PLoS One. 2010;5(10):e13772.
Valerio-Rojas JC, Jaffer IJ, Kor DJ, Gajic O, Cartin-Ceba R. Outcomes of severe sepsis and septic shock patients on chronic antiplatelet treatment: a historical cohort study. Crit Care Res Pract. 2013;2013:782573.
Winning J, Reichel J, Eisenhut Y, et al. Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets. 2009;20(1):50-57.
Tsai MJ, Ou SM, Shih CJ, et al. Association of prior antiplatelet agents with mortality in sepsis patients: a nationwide population-based cohort study. Intensive Care Med. 2015;41(5):806-813.
Eisen DP, Reid D, McBryde ES. Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis. Crit Care Med. 2012;40(6):1761-1767.
Vandijck DM, Blot SI, De Waele JJ, Hoste EA, Vandewoude KH, Decruyenaere JM. Thrombocytopenia and outcome in critically ill patients with bloodstream infection. Heart Lung J Acute Crit Care. 2010;39(1):21-26.